Natasha Rekhtman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Neuroendocrine tumors of the lung: an update
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1628-38. 2010
  2. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
  3. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
  4. doi request reprint Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
  5. doi request reprint Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
  6. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
  7. doi request reprint Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
  8. pmc EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cancer Ther 12:220-9. 2013
  9. doi request reprint Predicting pulmonary adenocarcinoma outcome based on a cytology grading system
    Carlie S Sigel
    1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York, USA
    Cancer Cytopathol 120:35-43. 2012
  10. doi request reprint Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Cytopathol 121:354-60. 2013

Collaborators

Detail Information

Publications20

  1. doi request reprint Neuroendocrine tumors of the lung: an update
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1628-38. 2010
    ..Markedly different prognostic implications and treatment paradigms for these tumors underscore the importance of accurate pathologic diagnosis...
  2. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
    ..These findings have practical implications for diagnosis, predictive molecular testing and therapy selection...
  3. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  4. doi request reprint Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  5. doi request reprint Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
    ..This simple algorithm achieves excellent accuracy in small specimens while conserving the tissue for potential predictive marker testing, which is now an essential consideration in advanced lung cancer specimens...
  6. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
    ..Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted...
  7. doi request reprint Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  8. pmc EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cancer Ther 12:220-9. 2013
    ..Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors...
  9. doi request reprint Predicting pulmonary adenocarcinoma outcome based on a cytology grading system
    Carlie S Sigel
    1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York, USA
    Cancer Cytopathol 120:35-43. 2012
    ..Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance...
  10. doi request reprint Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Cytopathol 121:354-60. 2013
    ....
  11. pmc Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66 Street, New York, NY 10065, USA
    Mol Cancer Ther 11:2535-40. 2012
    ..These tumors can mimic SCC in small samples. We propose an approach to increase the capture of these rare histology patients for EGFR mutation testing...
  12. doi request reprint Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma
    Andre L Moreira
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Electronic address
    Hum Pathol 45:213-20. 2014
    ..932) and was significantly worse than that for low- and intermediate-grade tumors (P = .0025). Complex glandular patterns have a significant prognostic value and should be considered patterns of high-grade adenocarcinoma. ..
  13. doi request reprint Progenitor stem cell marker expression by pulmonary carcinomas
    Andre L Moreira
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 23:889-95. 2010
    ..Therefore, stem cell markers are expressed in lung cancers with different patterns seen for different histological types and degrees of differentiation...
  14. pmc KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:1307-19. 2013
    ..Solid growth pattern was recently shown to be a strong predictor of aggressive behavior in lung adenocarcinomas, which may underlie the unfavorable prognosis associated with KRAS mutations in these tumors. ..
  15. doi request reprint Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
    Alexander Drilon
    Department of Medicine Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 13:e418-26. 2012
    ....
  16. doi request reprint Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Respir Crit Care Med 32:22-31. 2011
    ..The need for every institution to develop a multidisciplinary strategy to obtain these small specimens and process them not only for diagnosis but also for molecular testing is emphasized...
  17. pmc Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E, 66th Street, New York, NY, 10065, USA
    Cancer Chemother Pharmacol 72:931-4. 2013
    ..For cisplatin ineligible patients, there is no standard adjuvant option. We evaluated drug delivery and toxicity of docetaxel and vinorelbine in patients who could not receive cisplatin...
  18. pmc Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma
    Adnan Hasanovic
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Patholog Res Int 2011:897292. 2011
    ..In this paper we will review the current concepts in the suitability and accuracy of fine needle aspiration biopsy, including diagnosis, classification, prognostic markers, and use of ancillary techniques...
  19. doi request reprint Malignant solitary fibrous tumor: cytopathologic findings and differential diagnosis
    Justin A Bishop
    Department of Pathology, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Cancer Cytopathol 118:83-9. 2010
    ..Malignant solitary fibrous tumors (SFTs) are extremely uncommon and poorly understood mesenchymal neoplasms. There are only rare published accounts of the cytopathologic features of these tumors, prompting the current study...
  20. ncbi request reprint A 62-year-old woman with a suspected thyroid nodule
    Natasha Rekhtman
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Arch Pathol Lab Med 129:1497-8. 2005